-- 根據週三提交給香港交易所的文件顯示，InSilico Medicine（港交所代碼：3696）宣布，其吸入劑型Rentosertib的臨床試驗申請已獲得中國國家藥品監督管理局的批准。 該公司表示，該藥物擬用於治療特發性肺纖維化。 文件指出，此次批准將支持進行一項I期臨床試驗，以評估該藥物的安全性、耐受性和藥物動力學。
Related Articles
Asia
Brightstar Resources Reports Higher March Quarter Group Mining Production
Brightstar Resources (ASX:BTR) said its group mining production for the March quarter came in at 58,700 tonnes at 3.3 grams per tonne (g/t) grade of gold for 6,250 ounces from its Laverton underground mining operations in Western Australia, according to a Wednesday Australian bourse filing.The company's group mining production for the March 2025 quarter came in at 28,200 tonnes at 3.3 g/t grade of gold for 3,002 ounces from its Laverton underground mining operations in Western Australia, per the filing.During the quarter, the Fish underground mine was transitioned to care and maintenance, with mining operations ceasing and the mine positioned to be ready for the recommencement of ore production in early 2027.The mining development and closure proposal for Lady Shenton open pit mine in Menzies was approved, the filing said.Brightstar Resources' shares fell nearly 1% in recent trading on Wednesday.
$ASX:BTR
Asia
Racura Oncology, University of Wollongong Win New South Wales Government Funding for Cancer Study
Racura Oncology (ASX:RAC) and the University of Wollongong secured funding under the New South Wales government's TechVouchers program to study the efficacy of (E,E)-bisantrene for certain types of breast and ovarian cancers, according to a Wednesday filing with the Australian bourse.A collaboration between Racura and the University aims to produce preclinical evidence for the development of RC220 as a new targeted therapy, per the filing.Results from the collaboration are expected to come out over the next 12 months.Racura Oncology shares gained 2% in recent Wednesday trade.
$ASX:RAC
Asia
JAC Motors Widens Q1 Loss, Revenue Up 17%
Anhui Jianghuai Automobile (SHA:600418), or JAC Motors, posted first-quarter attributable net loss of 606.0 million yuan, compared with 223.0 million yuan the previous year.Loss per share widened to 0.27 yuan from 0.10 yuan, according to a Wednesday filing with the Shanghai bourse.The automobile company's operating revenue went up 17% year over year to 11.5 billion yuan from 9.80 billion yuan.
$SHA:600418